Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSR-042 + Radiation for Inoperable Endometrial Cancer
NCT03955978Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2019
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dostarlimab in endometrial cancer (EC), sponsored by Washington University School of Medicine. Primary endpoint: Safety and tolerability of the regimen as measured by the grade of toxicities experienced as assessed by CTCAE v5.0 at 10 weeks. Started Oct 2019; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03955978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955978.